These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38878765)

  • 21. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10.
    Wainberg ZA; Fuchs CS; Tabernero J; Shitara K; Muro K; Van Cutsem E; Bang YJ; Chung HC; Yamaguchi K; Varga E; Chen JS; Hochhauser D; Thuss-Patience P; Al-Batran SE; Garrido M; Kher U; Shih CS; Shah S; Bhagia P; Chao J
    Clin Cancer Res; 2021 Apr; 27(7):1923-1931. PubMed ID: 33446564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
    Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
    Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
    Kokka F; Bryant A; Brockbank E; Powell M; Oram D
    Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete remission of advanced and recurrent cervical cancer with pembrolizumab treatment- 3 case reports.
    Tung HJ; Wang CC; Liu FY; Lai CH
    Taiwan J Obstet Gynecol; 2021 Sep; 60(5):938-941. PubMed ID: 34507680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
    Martínez P; Del Campo JM
    Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving standards and future directions for systemic therapies in cervical cancer.
    Ang DJM; Chan JJ
    J Gynecol Oncol; 2024 Mar; 35(2):e65. PubMed ID: 38282261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in Cervical Cancer.
    Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
    Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
    Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P
    Front Immunol; 2021; 12():705096. PubMed ID: 34434192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
    Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
    J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival outcomes of neoadjuvant chemotherapy-related strategies compared with concurrent chemoradiotherapy for locally advanced cervical cancer: a meta-analysis of randomized controlled trials.
    Wang B; Tan Y; Yang X; Man X
    Arch Gynecol Obstet; 2021 Aug; 304(2):485-493. PubMed ID: 33389099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
    Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature.
    Chitsike L; Duerksen-Hughes P
    Curr Treat Options Oncol; 2020 Oct; 21(12):95. PubMed ID: 33025260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The management of locally advanced cervical cancer.
    Naga Ch P; Gurram L; Chopra S; Mahantshetty U
    Curr Opin Oncol; 2018 Sep; 30(5):323-329. PubMed ID: 29994902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of immunotherapy for advanced gastric cancer.
    Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
    Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer.
    Ge Y; Zhang Y; Zhao KN; Zhu H
    Drug Des Devel Ther; 2022; 16():3055-3070. PubMed ID: 36110399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
    Colombo N; Dubot C; Lorusso D; Caceres MV; Hasegawa K; Shapira-Frommer R; Tewari KS; Salman P; Hoyos Usta E; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Toker S; Li K; Keefe SM; Monk BJ;
    N Engl J Med; 2021 Nov; 385(20):1856-1867. PubMed ID: 34534429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer.
    Wu Y; Jiang P; Chen Z; Li W; Dong B; Zhang Y
    BMC Cancer; 2024 May; 24(1):589. PubMed ID: 38745137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.